Day 1  July 17, 2017

08:30-09:00 Registrations

Paris

conference.org  09:00-09:25  Opening Ceremony

Keynote Forum

09:25-09:30 Introduction
09:30-10:00 Title: Absence of Grail promotes CD8+ T cell anti-tumor activity  
               Roza Nurieva, MD Anderson Cancer Center, USA
10:00-10:30 Title: Novel antibody for cancer immunotherapy: beyond and synergistic with immune checkpoint blockade therapy  
               Jennifer Wu, Medical University of South Carolina, USA

Panel Discussion

Networking & Refreshments Break 10:30-10:50 @ Foyer

10:50-11:20 Title: Quantitative and Reproducible Cell-Based Bioassays to Advance Immunotherapy Programs  
               Gopal Krishnan, Promega Corporation, USA

Special Session

11:20-12:20 Title: A novel oncolytic HSV-1 vector for cancer immunotherapy  
               William Jia, University of British Columbia, Canada

Workshop

12:20-13:20 Title: Immunotherapy for thoracic cancers: challenges and success  
               Alessandra Curioni Fontecedro, University Hospital of Zurich, Switzerland

Group Photo

Panel Discussion

Lunch Break 13:20-14:20 @ Athens Rooms

Sessions: Immunotherapy - Tumors | Cancer Immunology & Immunotherapy | Cancer Research  
           Tumor Immunotherapy Research | Tumor Markers and Drug Targetting

Session Chair: Qiao Li, University of Michigan, USA
Session Chair: Roza Nurieva, MD Anderson Cancer Center, USA

Session Introduction

14:20-14:45 Title: Diagnostic and prognostic markers in Non-Hodgkin’s Lymphoma  
               Manal Mohamed Saber, Minia University, Egypt
14:45-15:10 Title: Oncologic impact of postoperative delta-neutrophil index in pancreatic cancer  
               Sung Hwan Lee, Yonsei University, Korea
15:10-15:35 Title: The tumor microenvironment is correlated with clinicopathological traits and indicates the adjuvant chemotherapeutic efficacy of gemcitabine in pancreatic cancer after curative Whipple procedure  
               Qiaofei Liu, Chinese Academy of Medical Sciences, China

Panel Discussion

Networking & Refreshments Break 15:35-15:55 @ Foyer

15:55-16:20 Title: Phase I clinical trials for the PD-1/MUC1 CAR-pNK92 immunotherapy  
               Leiming Xia, University of Michigan, USA
16:20-16:45 Title: Cancer stem cell vaccine significantly reduced local tumor relapse and prolonged animal survival in the adjuvant setting  
               Qiao Li, University of Michigan, USA

Panel Discussion
Day 2  July 18, 2017
Paris

Keynote Forum

10:00-10:30  Title: A Tetramer HLA-A Platform amenable to exchange peptides can be used to measure and predict the biological activity of a cancer vaccine  
Marc Delcommenne, Rush University Medical Center, USA

10:30-11:00  Title: Chimeric antigen receptor modified T cell redirected to EGFR in patients with metastatic and advanced pancreatic adenocarcinoma and biliary tract cancers  
Weidong Han, PLA General Hospital, China

Panel Discussion

Networking & Refreshments Break 11:00-11:20 @ Foyer

Sessions:
Immune System- Tumors | cancer Vaccines | Cancer Clinical Trials | Cancer Micro and Immuno Environment | Tumor Biology
Session Chair: Roza Nurieva, MD Anderson Cancer Center, USA
Session Chair: Qiao Li, University of Michigan, USA

11:20-11:45  Title: Emap II-Induced Immune Suppression In Colorectal Cancer  
Manal Mohamed Saber, Minia University, Egypt

11:45-12:10  Title: Adoptively transferred B cells directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways  
Lu Wen, University of Michigan, USA

12:10-12:35  Title: Comparative analysis of immune molecules in esophageal squamous cell carcinoma and adenocarcinoma  
Guohui Qin, Zhengzhou University, China

12:35-13:00  Title: Bacteria: friends or foes? Anticancer immune strategy by attenuated mutant strain of Salmonella Typhimurium (STMZNUABC)  
Barbara Chirullo, Istituto Superiore di Sanità, Italy

Panel Discussion

Lunch Break 13:00-14:00 @ Athens Rooms

Video Presentation

14:00-14:30  Title: Hiss Vaccine for treatment of cancer in early stages  
Hussein A Mohamed Ramadan, BSU University, Egypt

Poster Presentation @ 14:30-15:30

P1  Title: Mitochondrial DNA Copy Number Variation as a Potential Predictor of Renal Cell Carcinoma  
Eman Tayae Elsayed, Alexandria University, Egypt

P2  Title: T cell suppression is associated with circulating and tumor infiltrating CD33+11b+HLA-DR- myeloid suppressor cells in gastric cancer: A possible relation to MicroRNA-494 and TGF-β tumor expression  
Mai Moaaz, Alexandria University, Egypt

P3  Title: The Interplay of Interleukin-17A (IL-17A) and Breast cancer tumor microenvironment as a novel approach to increase tumor immunogenicity  
Mai Moaaz, Alexandria University, Egypt

P4  Title: Inhibition of Eva1 degrade the formation and development of glioblastomas  
Naoki Ohtsu, Hokkaido University, Japan

P5  Title: Clinical study of Hemagglutinating virus of Japan envelope against chemotherapy resistant pleural mesothelioma  
Chunmna Lee, Osaka University, Japan
Title: Is elevated troponin T reliable enough to be the only screen-out factor in pretreated lymphoma patients?
Nickolai Usachev, PSI Company, Ltd., Russia

Title: T Helper Subset Cell Activation and Activated T Cell Autonomous Death (ACAD) Dedicated by Peptidylarginine Deiminase 2 through an ER Stress and Autophagy Mechanism
Guang-Yaw Liu, Chung Shan Medical University Hospital, Taiwan

Title: A Novel Mechanism Regulating Polyamine Homeostasis through an Antizyme Citrullination Pathway
Hui-Chih Hung, National Chung Hsing University, Taiwan

Title: Anti-tumor and immunomodulatory effects of Cordyceps militaris polysaccharide fraction
Liyan Song, Jinan University, China

Title: FOXO1 promotes resistance of Non-Hodgkin lymphomas to anti-CD20-based therapy
Abdessamad Zerrouqi, Medical University of Warsaw, Poland

Panel Discussion
Networking & Refreshments Break 15:30-15:50 @ Foyer
Awards & Closing Ceremony

Bookmark your dates
3rd International Conference on Tumor & Cancer Immunology and Immunotherapy
September 17-18, 2018 San Diego, USA

E: tumor@immunologyconferences.org | cancer@immunologyconferences.org
W: tumorimmunology.conferenceseries.com